| Tag | Content |
|---|---|
| UniProt Accession | SRC8_HUMAN; Q14247; |
| Entrez ID | 2017 |
| GenBank Protein ID | NM_001184740.1; NM_005231.3; NM_138565.2; |
| GenBank Nucleotide ID | NP_001171669.1; NP_005222.2; NP_612632.1; |
| Protein Name | Src substrate cortactin (Amplaxin) (Oncogene EMS1) |
| Gene Name | CTTN; EMS1 |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Contributes to the organization of the actin cytoskeleton and cell shape (PubMed:21296879). Plays a role in the formation of lamellipodia and in cell migration. Plays a role in the regulation of neuron morphology, axon growth and formation of neuronal growth cones (By similarity). Through its interaction with CTTNBP2, involved in the regulation of neuronal spine density (By similarity). Plays a role in the invasiveness of cancer cells, and the formation of metastases (PubMed:16636290). Plays a role in focal adhesion assembly and turnover (By si(view all) |
| Sequence (Fasta) | MWKASAGHAV SIAQDDAGAD DWETDPDFVN DVSEKEQRWG AKTVQGSGHQ EHINIHKLRE 60 NVFQEHQTLK EKELETGPKA SHGYGGKFGV EQDRMDKSAV GHEYQSKLSK HCSQVDSVRG 120 FGGKFGVQMD RVDQSAVGFE YQGKTEKHAS QKDYSSGFGG KYGVQADRVD KSAVGFDYQG 180 KTEKHESQRD YSKGFGGKYG IDKDKVDKSA VGFEYQGKTE KHESQKDYVK GFGGKFGVQT 240 DRQDKCALGW DHQEKLQLHE SQKDYKTGFG GKFGVQSERQ DSAAVGFDYK EKLAKHESQQ 300 DYSKGFGGKY GVQKDRMDKN ASTFEDVTQV SSAYQKTVPV EAVTSKTSNI RANFENLAKE 360 KEQEDRRKAE AERAQRMAKE RQEQEEARRK LEEQARAKTQ TPPVSPAPQP TEERLPSSPV 420 YEDAASFKAE LSYRGPVSGT EPEPVYSMEA ADYREASSQQ GLAYATEAVY ESAEAPGHYP 480 AEDSTYDEYE NDLGITAVAL YDYQAAGDDE ISFDPDDIIT NIEMIDDGWW RGVCKGRYGL 540 FPANYVELRQ 551 |
|
||||||||||||||||||||||||||||||||||||||||||||||
| Database | Annotation |
|---|---|
| CTD (Curated) (count: 3) | MESH:D001171
; Arthritis, Juvenile MESH:D002294 ; Carcinoma, Squamous Cell MESH:D007971 ; Leukoplakia |
| DisGeNet (Curated) (count: 3) | C0007137; Squamous cell carcinoma
C0023531; Leukoplakia C3495559; Juvenile arthritis |
| GWASdb (count: 2) | rs12801756; Stroke; cerebrovascular disease
rs1198236; Multiple complex diseases; Null |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 69) (view all) | 104 KSAVGHEYQSKLSKH dbPAF
109 HEYQSKLSKHCSQVD dbPAF 11 ASAGHAVSIAQDDAG dbPAF 113 SKLSKHCSQVDSVRG dbPAF 117 KHCSQVDSVRGFGGK dbPAF 135 QMDRVDQSAVGFEYQ dbPAF |
| Acetylation (count: 14) (view all) | 107 VGHEYQSKLSKHCSQ PLMD
110 EYQSKLSKHCSQVDS PLMD 124 SVRGFGGKFGVQMDR PLMD 144 VGFEYQGKTEKHASQ PLMD 152 TEKHASQKDYSSGFG PLMD 161 YSSGFGGKYGVQADR PLMD |
| Ubiquitination (count: 16) (view all) | 124 SVRGFGGKFGVQMDR PLMD
144 VGFEYQGKTEKHASQ PLMD 161 YSSGFGGKYGVQADR PLMD 171 VQADRVDKSAVGFDY PLMD 181 VGFDYQGKTEKHESQ PLMD 198 YSKGFGGKYGIDKDK PLMD |
| Sumoylation (count: 4) | 144 VGFEYQGKTEKHASQ PLMD
181 VGFDYQGKTEKHESQ PLMD 218 VGFEYQGKTEKHESQ PLMD 295 DYKEKLAKHESQQDY PLMD |
| Glycation (count: 1) | 379 ERAQRMAKERQEQEE PLMD |
| Malonylation (count: 8) (view all) | 161 YSSGFGGKYGVQADR PLMD
171 VQADRVDKSAVGFDY PLMD 203 GGKYGIDKDKVDKSA PLMD 266 HESQKDYKTGFGGKF PLMD 272 YKTGFGGKFGVQSER PLMD 346 PVEAVTSKTSNIRAN PLMD |
| Succinylation (count: 3) | 226 TEKHESQKDYVKGFG PLMD
263 LQLHESQKDYKTGFG PLMD 359 ANFENLAKEKEQEDR PLMD |
| Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||